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Abstract
Background: There is little consensus, and minimal evidence, regarding the age at which to stop cervical screening. We
studied the association between screening at age 50–64 y and cervical cancer at age 65–83 y.
Methods and Findings: Cases were women (n= 1,341) diagnosed with cervical cancer at age 65–83 y between 1 April 2007
and 31 March 2012 in England and Wales; age-matched controls (n= 2,646) were randomly selected from population
registers. Screening details from 1988 onwards were extracted from national databases. We calculated the odds ratios (OR)
for different screening histories and subsequent cervical cancer. Women with adequate negative screening at age 65 y (288
cases, 1,395 controls) were at lowest risk of cervical cancer (20-y risk: 8 cancers per 10,000 women) compared with those
(532 cases, 429 controls) not screened at age 50–64 y (20-y risk: 49 cancers per 10,000 women, with OR= 0.16, 95% CI 0.13–
0.19). ORs depended on the age mix of women because of the weakening association with time since last screen: OR = 0.11,
95% CI 0.08–0.14 at 2.5 to 7.5 y since last screen; OR= 0.27, 95% CI 0.20–0.36 at 12.5 to 17.5 y since last screen. Screening at
least every 5.5 y between the ages 50 and 64 y was associated with a 75% lower risk of cervical cancer between the ages 65
and 79 y (OR = 0.25, 95% CI 0.21–0.30), and the attributable risk was such that in the absence of screening, cervical cancer
rates in women aged 65+ would have been 2.4 (95% CI 2.1–2.7) times higher. In women aged 80–83 y the association was
weaker (OR = 0.49, 95% CI 0.28–0.83) than in those aged 65–69 y (OR= 0.12, 95% CI 0.09–0.17). This study was limited by an
absence of data on confounding factors; additionally, findings based on cytology may not generalise to human
papillomavirus testing.
Conclusions: Women with adequate negative screening at age 50–64 y had one-sixth of the risk of cervical cancer at age
65–83 y compared with women who were not screened. Stopping screening between ages 60 and 69 y in women with
adequate negative screening seems sensible, but further screening may be justifiable as life expectancy increases.
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Introduction
There is a lack of consensus regarding the appropriate upper
age for cervical screening and little direct evidence on which to
base policy [1,2]. Until recently recommendations from the US
have been for women to be screened into their 80 s, and cervical
screening over age 65 y is common [3,4]. The current recom-
mendation from both the American Congress of Obstetricians and
Gynecologists and the American Cancer Society is that screening
should be stopped at age 65 y for women with evidence of
adequate prior negative screening and no history of cervical
intraepithelial neoplasia grade 2+ [5,6], but this recommendation
was based only on expert opinion and modelling because of the
lack of empirical data. More radically, in 1993, Van Wijngaarden
and Duncan [7] proposed that screening over the age of 50 y was
of little value in those previously well screened. However Rebolj et
al. [8] disagreed with these findings and reported a similar 10-y
cumulative incidence of cervical cancer in women whose third
consecutive negative test was taken at age 45–54 y and in those
whose third test was at age 30–44 y. Internationally, the upper age
for cervical screening varies from 59 or 60 y in Denmark, Finland,
and Scotland, to 70 y and over in Japan, Korea, and Uruguay [9].
In England and Wales women receive their last test between the
ages of 60 and 64 y. The justification for stopping screening in
older women is based on the natural history of cervical cancer.
Incident human papillomavirus (HPV) infections in women aged
55 y or over are rare and are unlikely to have sufficient time to
progress to invasive cancer in the woman’s lifetime. However, we
Table 1. Number and percent of invasive cervical cancer
cases by age, year of diagnosis, FIGO stage, and histology.
Characteristic n Percent
Age at Diagnosis
65–69 y 435 32.4%
70–74 y 404 30.1%
75–79 y 405 30.2%
80–83 y 97 7.2%
Year of diagnosis
2007 212 15.8%
2008 285 21.3%
2009 289 21.6%
2010 247 18.4%
2011 263 19.6%
2012 45 3.4%
FIGO stage
1A 63 4.7%
1B 267 19.9%
2+ 696 51.9%
Unknown 315 23.5%
Histology
Squamous cell carcinoma 940 70.1%
Adenocarcinoma 238 17.7%
Other 101 7.5%
Unknown 62 4.6%
Total 1,341 100%
doi:10.1371/journal.pmed.1001585.t001
T
a
b
le
2
.
R
is
k
o
f
ce
rv
ic
al
ca
n
ce
r
at
ag
e
6
5
–
8
3
y
b
y
sc
re
e
n
in
g
h
is
to
ry
at
ag
e
5
0
–
6
4
y.
S
cr
e
e
n
in
g
H
is
to
ry
a
t
A
g
e
5
0
–
6
4
y
a
C
a
se
s
C
o
n
tr
o
ls
O
R
w
it
h
N
o
S
cr
e
e
n
in
g
a
s
R
e
fe
re
n
ce
O
R
w
it
h
A
d
e
q
u
a
te
N
e
g
a
ti
v
e
S
cr
e
e
n
in
g
a
s
R
e
fe
re
n
ce
A
b
so
lu
te
R
is
k
(p
e
r
1
0
0
,0
0
0
W
o
m
e
n
p
e
r
Y
e
a
r)
2
0
-y
R
is
k
(p
e
r
1
,0
0
0
W
o
m
e
n
)
n
P
e
rc
e
n
t
n
P
e
rc
e
n
t
O
R
9
5
%
C
I
O
R
9
5
%
C
I
A
d
e
q
u
at
e
n
e
g
at
iv
e
2
8
8
2
1
.5
1
,3
9
5
5
2
.7
0
.1
6
0
.1
3
–
0
.1
9
1
R
e
fe
re
n
ce
4
.0
0
.8
Su
b
-o
p
ti
m
al
b
u
t
n
e
g
at
iv
e
3
0
0
2
2
.4
7
2
4
2
7
.4
0
.3
4
0
.2
8
–
0
.4
2
2
.1
5
1
.7
6
–
2
.6
4
8
.7
1
.7
A
b
n
o
rm
al
2
2
1
1
6
.5
9
8
3
.7
1
.8
3
1
.3
7
–
2
.4
3
1
1
.5
2
8
.5
7
–
1
5
.4
7
4
3
.0
8
.6
N
o
sc
re
e
n
in
g
5
3
2
3
9
.7
4
2
9
1
6
.2
1
R
e
fe
re
n
ce
6
.3
1
5
.1
7
–
7
.6
9
2
4
.5
4
.9
a
A
d
e
q
u
at
e
n
e
g
at
iv
e
:l
as
t
th
re
e
te
st
s
w
e
re
n
e
g
at
iv
e
(a
t
le
as
t
o
n
e
at
ag
e
6
0
–
6
4
y)
an
d
n
o
h
ig
h
-g
ra
d
e
(H
SI
L)
o
r
w
o
rs
e
cy
to
lo
g
y
si
n
ce
ag
e
5
0
.S
u
b
-o
p
ti
m
al
b
u
t
n
e
g
at
iv
e
:n
o
t
sa
ti
sf
yi
n
g
‘‘a
d
e
q
u
at
e
n
e
g
at
iv
e
’’
b
u
t
w
it
h
e
it
h
e
r
at
le
as
t
o
n
e
n
e
g
at
iv
e
te
st
an
d
n
o
ab
n
o
rm
al
te
st
s,
o
r
w
it
h
th
re
e
co
n
se
cu
ti
ve
n
e
g
at
iv
e
s
an
d
n
o
H
SI
L
b
u
t
w
it
h
th
e
la
st
te
st
b
e
fo
re
ag
e
6
0
.
A
b
n
o
rm
al
:
H
SI
L
cy
to
lo
g
y
o
r
a
lo
w
-g
ra
d
e
re
su
lt
(A
SC
-U
S
o
r
LS
IL
)
n
o
t
fo
llo
w
e
d
b
y
th
re
e
n
e
g
at
iv
e
s.
N
o
sc
re
e
n
in
g
:
n
o
te
st
at
ag
e
5
0
–
6
4
y.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
m
e
d
.1
0
0
1
5
8
5
.t
0
0
2
Impact of Screening on Cervical Cancer Age 65+
PLOS Medicine | www.plosmedicine.org 2 January 2014 | Volume 11 | Issue 1 | e1001585
know of no direct evidence of the impact of cervical screening in
older women in the period 7 to 15 y after their last screening test.
We studied the association between screening women at age
50–64 y and cervical cancer diagnosed at age 65–83 y. Our aim
was to provide policy-makers with evidence to help address the
following questions. (1) Are well-screened women with a history of
negative tests and no high-grade results at sufficiently low risk of
cervical cancer that screening can cease at age 65? If so, how low is
their risk, and how does it change as they age? (2) Are women who
regularly participate in screening at age 50–64 y at reduced risk of
cervical cancer at age 65–83 y?
Methods
Ethics Statement
The collection of data as part of this audit has been approved
since 2003 (PIAG 1-08(a)/2003) under Section 251 of the National
Health Service Act 2006, which re-enacted Section 60 of the
Health and Social Care Act 2001. The analysis of anonymised
data in this context is considered service evaluation and therefore
according to UK guidelines is considered ethical without further
consideration by a research ethics committee [10].
Participants
There is free universal health care in England and Wales
provided by the National Health Service (NHS), and all adult
females registered with the NHS have a record in the national
Cervical Screening Call/Recall System. Cases were women aged
65 y or older who were diagnosed with cervical cancer (ICD-10
C53) in England (between 1 April 2007 and 31 March 2012) and
Wales (between 1 January 2007 and 31 December 2009) (October
2012 dataset) and who were registered with an NHS general
practitioner (GP). Any other woman registered with an NHS GP
at the time of a case diagnosis was eligible as a control for that
case. Controls were randomly selected (using a computer program)
from women satisfying the matching criteria. Two controls were
individually matched to each case based on age and place of
residence: one control had the same GP as the case, and a second
control had a different GP but was within the same administrative
area. Occasionally, only one control could be identified. The study
design did not allow for collection of data on potential confounders
such as sexual behaviour, parity, and smoking. Matching on the
same GP was to provide a crude surrogate for socio-economic
status and ethnicity. The reason for selecting a control from a
different GP was to avoid overmatching if screening uptake was
dependent on the GP’s enthusiasm for cervical screening. Data
were collected on all selected controls, so there was no study
selection or participation bias.
Data on screening histories were abstracted from routinely
recorded cervical cytology records held on the Cervical Screening
Call/Recall System (and as such were not subject to recall bias).
These records include all NHS (and many private provider) smears
taken in the UK since 1988.
After local NHS staff linked screening data to cases and
controls, the data were anonymised locally before being
transferred for cleaning and analysis. Guidelines on the collection
of data for this audit and details of the design have been published
previously [11–13].
Delays in the inclusion of newly diagnosed cancers in our audit
resulted in advanced stage cancers and cases diagnosed in the most
recent period being underrepresented. It was estimated that the
database contained 78% of all cancers in women aged 65–83 y
diagnosed during the study period in England [14].
Women aged 60 y or over on 1 January 1988 were excluded
because they may not have been invited for screening as part of
the Cervical Screening Call/Recall System; therefore, relatively
few women in the study were diagnosed with cancer over the age
of 80.
Figure 1. Odds ratio of cervical cancer at age 65–83 y in those with adequate negative screening compared with no screening at
age 50–64 y by age at diagnosis. The line shows the log-linear trend, the shaded area shows the 95% confidence interval for the trend line, and
the dots provide estimates based on data within 2 y of the x-axis values.
doi:10.1371/journal.pmed.1001585.g001
Impact of Screening on Cervical Cancer Age 65+
PLOS Medicine | www.plosmedicine.org 3 January 2014 | Volume 11 | Issue 1 | e1001585
Cytology results were classified according to the British Society
for Clinical Cytology system [15]. The British Society for Clinical
Cytology terminology can be broadly compared to the Bethesda
System, as follows: ‘‘borderline changes’’ include atypical squa-
mous cells, atypical glandular cells, and ‘‘borderline, high-grade
dyskaryosis not excluded’’ (equivalent to the Bethesda System’s
ASC-H); ‘‘mild dyskaryosis’’ corresponds to low-grade squamous
intraepithelial lesion (LSIL); ‘‘moderate and severe dyskaryosis’’
corresponds to high-grade squamous intraepithelial lesion (HSIL);
and there are separate categories, ‘‘query invasive’’ and ‘‘query
glandular neoplasia’’, for squamous cell carcinoma and adenocar-
cinoma in situ/cervical glandular intraepithelial neoplasia/adeno-
carcinoma, respectively. Tests classified as ‘‘inadequate’’ should
have resulted in immediate repeat testing and were therefore
ignored in this analysis. The exception was when they resulted in a
referral to colposcopy (guidelines recommended referral after a
third consecutive inadequate test).
Statistical Analysis
We used conditional logistic regression to estimate the odds
ratio (OR) of cervical cancer (at age 65 y or older) for women with
various screening patterns compared to those with no cervical cyto-
logy (except possibly inadequate test[s] not resulting in referral)
between the ages 50 and 64 y. To exclude screen-detected cancers
(diagnosed following screening at age 64 y), we excluded women
(including control women) diagnosed at age 65.0–65.5 y with a
cytology test within 6 mo of case diagnosis. Age of diagnosis was
defined for controls using the date of diagnosis for their matched case.
We calculated absolute risks using a weighted logistic regression
model, with weights calculated by case status, age category (65–69,
70–74, 75–79, and 80–84 y), and year of diagnosis. Weights for
cases were calculated as the total number of cases diagnosed
(according to the official cancer registration statistics for England
[MB1 series] [16] [age-specific data for 1975–2011 were prepared
by Cancer Research UK] and for Wales [17]) divided by the
number recorded in the audit (see Table S1). As official figures
have not yet been published for 2012, the 2011 weights were used.
For controls, for each year of diagnosis and age group, the weights
were calculated using the following formula:
control weight~
case weight|ratio of cases to controls
incidence rate in population
ð1Þ
Cervical cancer incidence rates were calculated as the number of
cases diagnosed according to the MB1 series divided by the mid-
year population estimate. We used the ORs and the percentage of
cases in each category to calculate the population attributable risk
(under the assumption of the association being causal) in two ways.
Figure 2. Subgroup analyses—odds ratios of cervical cancer at age 65–83 y for women with adequate negative screening relative
to no screening at age 50–64 y.
doi:10.1371/journal.pmed.1001585.g002
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We calculated how much greater cervical cancer rates (in women
aged 65–79 y) would have been in the absence of screening
beyond age 50. Additionally, we calculated the proportion of
cancers (that did occur) that might have been prevented had all
women been screened at least every 5.5 y between the ages 50 and
64 y. Confidence intervals for the population attributable risks
were calculated by bootstrapping (percentile method based on
2,000 replications).
We studied the association between cervical screening at age
50–64 y and the risk of cervical cancer at age 65–83 y by
answering the following questions. (1) What is the risk of cervical
cancer at age 65 y and older in women with a history of negative
tests and no high-grade results at age 50–64 y? Does the risk
relative to women not screened at age 50–64 y change with time
since last test (i.e., as women age)? (2) What is the risk of cervical
cancer at age 65–83 y in women who regularly participate
(defined as having a test at least every 5.5 y) in screening at age
50–64 y compared with the risk in women not screened at all at
age 50–64 y?
To address the first question, screening histories for women
between the ages of 50 and 64 y were divided into four categories:
(1) ‘‘adequate negative screening’’, defined as women with at least
three tests at age 50–64 y (with at least one at age 60–64 y), the
last three of which were negative, and no HSIL or worse cytology
since age 50; (2) ‘‘sub-optimal but negative screening’’, defined as
women not satisfying ‘‘adequate negative screening’’ but with
either at least one negative test and no abnormal tests, or with
three consecutive negative tests and no HSIL, but the last test was
under age 60; (3) ‘‘abnormal screening’’, defined as women with
HSIL cytology at age 50–64 y, regardless of whether or not it was
followed by three consecutive negatives, or with a low-grade result
(atypical squamous cells of undetermined significance [ASC-US]
or LSIL) that was not followed by three consecutive negatives; (4)
‘‘no screening’’, defined as women with no test at age 50–64 y
Table 3. Risk of cervical cancer according to screening history
at age 50–64 y by age at diagnosis.
Screening History Cases (n) Controls (n) OR 95% CI
Age at diagnosis 65–69 y
Adequate negative 73 539 0.07 0.05–0.11
Sub-optimal but negative 66 166 0.22 0.15–0.33
Abnormal 83 46 0.92 0.58–1.47
No screening 213 108 1 Reference
Age at diagnosis 70–74 y
Adequate negative 115 488 0.18 0.13–0.25
Sub-optimal but negative 78 174 0.38 0.25–0.56
Abnormal 72 28 2.20 1.31–3.70
No screening 139 117 1 Reference
Age at diagnosis 75–79 y
Adequate negative 86 326 0.28 0.20–0.41
Sub-optimal but negative 121 294 0.45 0.33–0.63
Abnormal 56 21 3.04 1.67–5.54
No screening 142 157 1 Reference
Age at diagnosis 80–83 y
Adequate negative 14 42 0.37 0.16–0.82
Sub-optimal but negative 35 90 0.46 0.25–0.82
Abnormal 10 3 5.34 1.12–25.46
No screening 38 47 1 Reference
doi:10.1371/journal.pmed.1001585.t003
Figure 3. Odds ratio of cervical cancer in those with adequate negative screening compared with no screening at age 50–64 y by
time since last screen. The line shows the log-linear trend, the shaded area shows the 95% confidence interval for the trend line, and the dots
provide estimates based on data within 2 y of the x-axis values.
doi:10.1371/journal.pmed.1001585.g003
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(excluding inadequate tests not resulting in referral to colposcopy).
The first category approximates the group that the American
Congress of Obstetricians and Gynecologists would discharge
from screening. As we have no access to histology records of
cervical intraepithelial neoplasia, we cannot identify those with
cervical intraepithelial neoplasia grade 2+ and instead exclude
women with HSIL cytology at any time since age 50.
Attenuation of the OR with increasing age was investigated
non-parametrically (ORs were calculated separately for individuals
diagnosed at different ages using overlapping 4-y intervals every
6 mo from age 65.0–69.0 y to age 79.0–83.0 y) and parametrically
(a trend line and 95% confidence interval were calculated by
including an interaction term between negative screening and age
at diagnosis in the regression model). We also studied the risk of
cervical cancer in women with at least three consecutive negative
tests and no HSIL cytology at age 50–64 y by time since last test
(at age 50–64 y).
To address the second question (if screening per se is associated
with a lower risk of cervical cancer), a woman’s (maximum)
screening interval was defined as the longest period during the
15 y from age 50 to age 64 y in which she did not have an
adequate cytology test (for women who were over 50 y in 1988, we
considered only the interval from 1 January 1988 until their 65th
birthday). In England and Wales, women in this age group were
invited either every 3 y or every 5 y (depending on local policy at
the time); therefore, we defined women whose maximum interval
between tests during the 15 y period under study was at most 5.5 y
to have attended screening regularly. Women with only inade-
quate tests were considered not to have been screened at age 50–
64 y unless referred to colposcopy as a result of the inadequate
cytology, in which case they were considered to be in category 3,
‘‘abnormal screening’’.
The main analyses were repeated in a number of subgroups
(e.g., by histological type) and with a number of exclusions (e.g.,
considering only cancers known to be stage 1B or worse).
Additionally, we performed a sensitivity analysis of the possible
impact of unknown confounders (such as smoking or number of
sexual partners) on our results, and estimated the potential impact
Table 4. Risk of cervical cancer at age 65–83 y by screening history at age 50–64 y and histological type.
Screening History at Age 50–64 ya Cases Controls OR 95% CI
n Percent n Percent
Squamous cell carcinoma
Adequate negative 149 15.9 979 52.7 0.11 0.09–0.14
Sub-optimal but negative 202 21.5 502 27.0 0.31 0.25–0.40
Abnormal 179 19.0 75 4.0 1.80 1.29–2.53
No screening 410 43.6 300 16.2 1 Reference
Adenocarcinoma
Adequate negative 79 33.2 241 51.3 0.36 0.23–0.56
Sub-optimal but negative 61 25.6 136 28.9 0.51 0.32–0.82
Abnormal 30 12.6 15 3.2 2.07 1.05–4.10
No screening 68 28.6 78 16.6 1 Reference
Other
Adequate negative 41 40.6 114 57.6 0.27 0.13–0.55
Sub-optimal but negative 23 22.8 49 24.7 0.38 0.18–0.82
Abnormal 6 5.9 7 3.5 0.70 0.19–2.46
No screening 31 30.7 28 14.1 1 Reference
aAdequate negative: last three tests were negative (at least one at age 60–64 y) and no high-grade (HSIL) or worse cytology since age 50. Sub-optimal but negative: not
satisfying ‘‘adequate negative’’ but with either at least one negative test and no abnormal tests, or with three consecutive negatives and no HSIL but with the last test
before age 60. Abnormal: HSIL cytology or a low-grade result (ASC-US or LSIL) not followed by three negatives. No screening: no test at age 50–64 y.
doi:10.1371/journal.pmed.1001585.t004
Table 5. Risk of cervical cancer at age 65–79 y by maximum screening interval between the ages 50 and 64 y.
Screening Interval at Age 50–64 y Cases Controls OR 95% CI
n Percent n Percent
Not screened at age 50–64 y 510 41.0 411 16.7 1 Reference
#3.5 y 149 12.0 464 18.8 0.27 0.21–0.34
3.5–5.5 y 326 26.2 1,060 43.0 0.25 0.20–0.30
5.5–9 y 150 12.1 369 15.0 0.34 0.26–0.43
9–15 y 109 8.8 160 6.5 0.54 0.40–0.71
#5.5 y 475 38.2 1,524 61.9 0.25 0.21–0.30
doi:10.1371/journal.pmed.1001585.t005
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of changing the age at last screen on cervical cancer rates. We
considered a risk score of the sort obtained from questionnaire
data (not including screening attendance), divided into five risk
levels, with 10% of screened women in each of the extreme
groups, 20% in each of the high- and low-risk groups, and 40% in
the middle group. We allowed for a 5-fold difference in risk
between the highest and lowest risk groups, a difference in risk we
believe to be plausible but extreme [18]. We assumed that the
distribution of risk levels in unscreened women is a logistic shift of
the distribution in screened women (shifted by 2ln[2.25])
corresponding to an OR of 4.25 between the extreme groups.
Analyses were done in STATA 12 (StataCorp).
Results
A total of 1,341 women with invasive cervical cancer diagnosed
at age 65–83 y and 2,646 matched controls were included in the
study. Thirty-six cases (2.7%) had only one control—either
because, for example, the other potential control was born before
1928 and the case was not, or because only one control that
fulfilled the matching criteria was found. The distribution of cases
by age, year of diagnosis, International Federation of Gynecology
and Obstetrics (FIGO) stage, and histology is shown in Table 1.
Similar numbers of women (404–435) were diagnosed in each 5-y
age group for 65–79 y, but only 97 women were aged 80–83 y.
Most of the cancers in this study were diagnosed as FIGO stage 2
or worse, and over 70% were squamous cell carcinoma.
Table 2 shows the risk of cervical cancer diagnosed at age 65–
83 y by screening history in the age interval 50–64 y. The highest
risk was observed in those with a history of abnormal cytology
(OR=1.83, 95% CI 1.37–2.43, when compared with women
without any tests at age 50–64 y). Women with cervical cancer
were more likely to have had no screening at age 50–64 y than the
general population (40% versus 16%) and less likely to have had
adequate negative screening (21% versus 53%). Women with
adequate negative screening were approximately six times less
likely to be diagnosed with cervical cancer at age 65 y or older
(OR 0.16, 95% CI 0.13–0.19) compared with women with no
(adequate) tests since age 50.
The OR for cervical cancer in the adequate negative screening
group increased with age (Figure 1), from 0.07 (95% CI 0.05–0.11)
for ages 65–69 y to 0.28 (95% CI 0.20–0.41) for ages 75–79 y and
to 0.37 (95% CI 0.16–0.82) for ages 80–83 y (Figure 2; Table 3).
Similarly, in women whose last three tests were negative and who
had no HSIL results at age 50–64 y, the low risk associated with a
negative screen weakened with time since last screen (Figure 3).
The OR was 0.11 (95% CI 0.08–0.14) for women diagnosed
within 2.5 to 7.5 y of their last screen, but the OR was 0.27 (95%
CI 0.20–0.36) for those diagnosed 12.5 to 17.5 y after the last
screen. There was no evidence that this tapering effect depended
Figure 4. Subgroup analyses—odds ratios of cervical cancer at age 65–79 y for women screened at least every 5.5 y at age 50–64 y
relative to no screening at age 50–64 y.
doi:10.1371/journal.pmed.1001585.g004
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on the age at last screen, but we had little power to address this
issue, as 80% of women with three negatives had their last test
between 60.9 and 64.6 y of age.
Based on cervical cancer incidence in women aged 65–84 y in
2007–2011, we estimated the absolute rate per 100,000 woman-years
to be 4.0 in adequately negatively screened women, 24.5 in
unscreened women, and 43.0 in women with an abnormal screen-
ing history. These absolute risks translate to a 20-y risk per 10,000
women of eight for adequately negatively screened women and 86
for those with abnormal screening.
The OR of squamous cell carcinoma (Table 4; Figure 2)
associated with adequate negative screening was lower than for all
cervical cancer (OR=0.11, 95% CI 0.09–0.14), whereas the OR
for adenocarcinoma of the cervix was greater (OR=0.36, 95% CI
0.23–0.56).
To explore the effect of screening per se (as opposed to the
association with negative screening), we estimated the association
(OR) between a diagnosis of cervical cancer at age 65–83 y and
the maximum screening interval at ages 50–64 y (Table 5). The
lowest risk was seen for those with a screening interval of #5.5 y
(OR=0.25, 95% CI 0.21–0.30, compared with those with no
screen recorded at age 50–64 y): screening intervals of #3.5 y
were no more ‘‘protective’’ than those of 3.5–5.5 y. Even women
with a screening interval of 9–15 y had significantly lower risk
than those not screened at all at age 50–64 y (OR=0.54, 95% CI
0.40–0.71). The lower risk associated with the currently recom-
mended screening every 5 y (interval #5.5 y) at ages 50–64 y
diminished with increasing age at diagnosis: 65–69 y, OR=0.12
(95% CI 0.09–0.17); 70–74 y, OR=0.27 (95% CI 0.19–0.36); 75–
79 y, OR=0.46 (95% CI 0.35–0.61); and 80–83 y, OR=0.49
(95% CI 0.28–0.83) (Figure 4; Table 6).
The estimated ORs depended on the age at diagnosis and
histological type, but were otherwise very similar in different
subgroups (Figures 2 and 4). Restricting analysis to cases known to
have stage 1B or worse cancer or to cases born since 1938 gave
(age-specific) ORs that were extremely similar to those without
such restrictions. Similarly, the results were extremely similar using
either only the GP control or only the district control.
Treating the associations in Table 5 as causal, we estimated that
in the absence of screening at ages 50–64 y, cervical cancer rates
in women aged 65–79 y (currently 9.6 per 100,000 woman-years)
[19] would have been 2.42 (95% CI 2.11–2.71) times higher (i.e.,
23 per 100,000 woman-years). Conversely, had all women been
screened at intervals of #5.5 y between the ages 50 and 64 y,
population rates of cervical cancer in women aged 65–79 would
have been 38% (95% CI 32%–42%) lower than those observed
(corresponding to a rate of 5.9 per 100,000 woman-years).
It is possible that the distribution of risk factors (other than
cervical screening) for cervical cancer differed between screened
and unscreened women. Taking what we consider to be a plausible
but extreme scenario (Table 7), resulted in an 18% (= 1/0.8521)
increase in the estimated ORs, i.e., the ORs of cervical cancer in
regularly screened women compared with never screened women
would be 0.14 for women aged 65–69 y, 0.32 for women aged 70–
74 y, and 0.54 for women aged 75–79 y.
For illustration of what might be the effect of changing the age
at last screen, we have estimated the potential impact of stopping
screening at age 65 y (as per our data), age 55, or age 75 y
(Table 8). In 1975 the cumulative incidence was 892 cervical
cancers per 100,000 women. With screening until age 65, this
value would be reduced to 211 using the ORs from this study as
relative risks, and 250 with the adjustment for unobserved
confounding. Using the observed relative risks, there would be
an additional 182 cancers if cervical cancer screening ceased at age
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55, and 103 fewer if it continued until age 75. Interestingly, the
added benefit of prolonged screening is greater with the adjusted
relative risks: 216 additional cervical cancers when stopping
screening at age 55, and 122 fewer when continuing screening to
age 75.
Discussion
This study showed that women with adequate negative
screening at age 50–64 y (women whose last three tests were
negative [with at least one at age 60–64 y] and who had no high-
grade cytology between the ages of 50 and 64 y) were at
particularly low risk of being diagnosed with cervical cancer at
age 65 y or older: the risk is 84% less than in unscreened women.
The 20-y absolute risk of cervical cancer was eight per 10,000
women in those so screened compared to 49 per 10,000 women in
those not screened between the ages of 50 and 64 y. Similarly, low
risk of cervical cancer was observed among women whose interval
between tests at ages 50–64 y was no greater than 5.5 y. The
‘‘protection’’ of adequate negative screening at age 50–64 y was
greater for women aged 65–69 y and decreased steadily with time
since last negative screen. It was considerably less 15 y after
screening than 10 y after screening. Similarly, regular screening
(interval #5.5 y) at ages 50–64 y was associated with a low risk of
cervical cancer until age 75; thereafter, the ‘‘effect’’ of screening
weakened, and by age 80 y the risk in well-screened women was
about half the risk of unscreened women. These results were
robust to a number of sensitivity analyses.
This is the largest study looking at cervical screening and the
risk of cervical cancer at age 65 y and older. Controls were
automatically selected from the database of all women invited for
cervical screening in England and Wales, minimising the selection
bias, and linkage was used to obtain all screening histories,
ensuring completeness of the data and no recall bias. The design (a
population-based case control study) allowed estimation of
absolute risks.
The main limitation of this observational study is that the
database containing screening histories (from which the controls
were identified) did not record information on risk factors. The
association with screening in this study is greater for squamous cell
carcinoma than for adenocarcinoma. The risk factors for both
histological types are similar [18], and the vast majority of in situ
lesions detected by screening are squamous cell carcinomas [20].
Together these three facts suggest that the greater association with
squamous cell carcinoma is due to screening and not confounding.
Additionally, the association was greater within 5 y (compared
with 12.5–17.5 y) of screening, and we see no reason why the
impact of unrecorded risk factors would change with time from
last screen. Note that screening was not offered and was extremely
rare after the age of 64 y, and coverage in women aged 50–64 y
has been stable at about 80% over the last 16 y [20,21].
Nevertheless, the underlying risk of cervical cancer in a woman
who has never been screened may be greater than in a woman
who is screened regularly. However, the only study that we could
find of screening and cervical cancer that adjusts for risk factors
(smoking) found that the adjusted and unadjusted ORs were
similar [22]. Further, a study comparing never-attenders at
cervical screening to attenders in Denmark found that never-
attenders had no overrepresentation of cancer risk factors [23]. A
small number of women in our cohort may have been screened
before 1988 but not since, and we would not know about such
early screening. However, analyses restricted to women who were
under age 50 y in 1988 did not substantially change the age-
specific effects of screening. Another limitation of our study is that
we had only 97 cases over age 80 y and none over age 83 y, so
estimates beyond age 80 y have wider confidence intervals, and we
are unable to say what happens 20 y after the last screen taken at
age 60–64 y (i.e., in women adequately negatively screened).
There has been only limited evidence and a lack of consensus
regarding the optimal upper limit for screening. Even at younger
ages there has been little study of the risk of cervical cancer more
than 6 y after the last screening test. A smaller study by Kamineni
et al. [22] including 69 cases in women aged 55–79 y (with a
maximum time since last negative test of 7 y) also found a
reduction in risk of developing cervical cancer within 5 y of the last
negative test.
Our results do not give cause for concern regarding the current
US recommendations to cease cervical screening in previously
well-screened women at age 65 y. This recommendation has been
supported by recently published data from a study in northern
California [24]. However, while screening at age 50–64 y offers
some protection long term, the magnitude of the protection
decreases with time.
Screening in older women can be uncomfortable, and a lack of
oestrogen can make obtaining an adequate cytology sample and
interpreting it difficult. Although HPV testing on a sample
collected without a speculum would overcome these problems
for women testing HPV negative, those testing positive would still
(currently) require cytology triage, and some would require
colposcopy. Further, those women who test positive for HPV
but who have normal cytology (approximately 4% [25]) pose a
challenge for clinical management. Indeed, in the context of
primary HPV screening, there will be the need for ongoing
reassessment about the optimal age of stopping screening in
relation to screening history.
The absolute risks in this paper are based on current rates of
cervical cancer in older women in England. The absolute impact
in the UK may be greater over the next 15 y because of the
Table 7. Estimated relative risks of cervical cancer associated with questionnaire-type risk factor data (e.g., economic deprivation,
number of sexual partners, and smoking).
Statistic Risk Level Weighted Average Risk Relative Risk
Very Low Low Medium High Very High
Relative risk 0.4 0.7 1.0 1.4 2.0
Screened (percent with risk
factor)
10.0 20.0 40.0 20.0 10.0 1.06 0.85
Not screened (percent with
risk factor)
4.7 11.3 34.9 29.1 20.0 1.25
doi:10.1371/journal.pmed.1001585.t007
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increasing underlying risk in cohorts born since 1950 [26–28].
Applying the same relative risks to a population with an underlying
age-specific annual rate of cervical cancer of about 80 per 100,000
women between the ages 65 and 79 y, for every 1,000 women
screened regularly between the ages 50 and 64 y, there would be
approximately nine fewer cancers between the ages of 65 and
79 y.
Taken with the considerable evidence that cervical screening
causally reduces cervical cancer incidence [29], the results here
suggest that screening women aged 50–64 y substantially reduces
their risk of cervical cancer at age 65 y and older, but that the
magnitude of that protection decreases with time since last screen.
The low risk of cervical cancer in those with a test at least every
5.5 y from age 50 to age 64 y (OR=0.25) can to a large extent be
attributed, in the authors’ view, to the protection offered by
screening. Based on this result, we estimated the annual rate of
cervical cancer in the absence of screening to be 25 per 100,000
women. Interestingly this rate is slightly lower than the rate in
women aged 65–79 y in England (27.6 per 100,000) before the
screening programme was introduced (i.e., 1975–1988) [16].
The lower OR associated with adequate negative screening
(0.16) than with regular screening (0.25) represents the ability of
screening to identify those at particularly low risk of developing
cancer in the following few years. This finding suggests that the
guidelines recommending that women should exit screening only if
their last three tests were all normal (and they satisfy the criteria for
being adequately negatively screened) are sensible. Similarly, the
high risk of cervical cancer (20-y absolute risk of 0.86%) in women
with an unresolved abnormal test result in their history when they
reach age 65 y emphasises the need for continued surveillance for
such women (at least until three consecutive negatives are
obtained). Among those with adequate negative screening, ceasing
screening at age 50 y is unlikely to provide lifelong protection, but
continuing screening till age 80 y is not necessary. As life
expectancy increases (at age 65 y it is about 20 additional years
for women in many industrialised countries [30]), consideration
should be given to increasing the upper age of screening, possibly
by extending the final screening interval from 5 to 10 y. This study
provides evidence that should help produce cost-effectiveness
analyses that would enable policy-makers to reach a rational
decision.
Cervical screening is changing; most countries with organised
screening have moved from conventional cytology to liquid-based
cytology, and many are now considering primary HPV testing.
This study was done within the UK with a mix of conventional
cytology and liquid-based cytology, and as such, these results may
not be generalisable to HPV-based screening programmes. Since
the long-term negative predictive value of HPV testing is even
better than that of cytology, one would expect the period of low
risk to be longer following an HPV test, but there are currently no
studies looking at the risk 15–20 y after a negative HPV test.
Cervical screening in women aged 50–64 y has a substantial
impact on cervical cancer rates not only at age 50–64 y, but for
many years thereafter. Screening up to age 65 y greatly reduces
the risk of cervical cancer in the following decade, but the
protection weakens with time and is substantially less 15 y after the
last screen. In the light of increasing life expectancy, it would seem
inappropriate for countries that currently stop screening between
the ages 60 and 69 y to consider reducing the age at which
screening ceases. To the contrary, consideration should be given to
cost-effective ways of increasing the age of the last screening.
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Editors’ Summary
Background. Nearly one in ten cancers diagnosed in
women occur in the cervix, the structure that connects the
womb to the vagina. Every year, more than a quarter of a
million women (mostly in developing countries) die because
of cervical cancer, which occurs only after the cervix has
been infected with human papillomavirus (HPV) through
sexual intercourse. In the earliest stages of cervical cancer,
abnormal cells begin to grow in the cervix. Cells with low-
grade abnormalities (changes that often revert to normal),
cells with high-grade abnormalities (which are more likely to
become cancerous), and cancer cells can all be detected by
collecting a few cells from the cervix and examining them
under a microscope. This test forms the basis of cervical
screening, which has greatly reduced cervical cancer deaths
in countries with a national screening program by ensuring
that cervical abnormalities are detected at an early, treatable
stage. In the UK, for example, since the start of a cervical
screening program in 1988 in which women aged 25–64
years are called for testing every 3–5 years, the incidence of
cervical cancer (the number of new cases per year) has
almost halved at a time when sexually transmitted diseases
have more than doubled.
Why Was This Study Done? Currently, there is little
consensus about the age at which cervical screening should
stop, and minimal evidence about the impact of cervical
screening on the incidence of cervical cancer in older
women. In this population-based case control study (a study
that compares the characteristics of all the cases of a disease
in a population with the characteristics of matched individ-
uals without the disease), the researchers examine the
association between screening in women aged 50–64 years
and cervical cancer in women aged 65–83 years. They ask
whether well-screened women with a history of negative
results and no evidence of high-grade abnormalities are at
sufficiently low risk of cervical cancer that screening can be
stopped at age 65 years, and whether women who are
regularly screened (at least once every 5.5 years) between
the ages of 50 and 64 years are subsequently at reduced risk
of cervical cancer.
What Did the Researchers Do and Find? The researchers
randomly selected two age-matched controls for every
woman aged 65–83 years who was diagnosed with cervical
cancer between 2007 and 2012 in England and Wales. The
researchers included 1,341 women with cervical cancer and
2,646 controls. They extracted each woman’s cervical
screening details from national databases and calculated
the association between screening history and subsequent
cervical cancer. Women with adequate negative screening at
age 65 years (at least three tests at age 50–64 years with the
last one over age 60, the last three of which were negative,
and no evidence of high-grade abnormalities) were at the
lowest risk of cervical cancer (20-year risk of eight cancers
per 10,000 women) compared with unscreened women (20-
year risk of 49 cancers per 10,000 women). That is, women
who were not screened at age 50–64 years were six times
more likely to develop cervical cancer between the ages of
65 and 83 years than women who were screened. The risk of
developing cervical cancer among adequately negatively
screened women increased with age and with time since the
last screen. Finally, the researchers estimate that in the
absence of any cervical screening, the rate of cervical cancer
among women aged 65–79 years would be 23 cases per
100,000 woman-years, 2.4 times higher than the current rate.
What Do These Findings Mean? These findings show
that women who exited the screening program in England
and Wales with a history of adequate negative screening
between the ages of 50 and 64 years were at a very low risk
of being diagnosed with cervical cancer at the age of 65
years or older. The ‘‘protection’’ provided by screening was
greatest for women aged 65–69 years and decreased steadily
with increasing age and with time since the last negative
screen. Because the researchers did not have any informa-
tion on other characteristics that might have affected
cervical cancer risk (for example, number of sexual partners),
the women who were screened may have shared other
characteristics that reduced their risk of developing cervical
cancer. Moreover, these findings, which are based on
microscopic examination of cells, may not generalise to the
HPV-based screening programs that many countries are
considering. Despite these limitations, the researchers
conclude that, for now, it seems sensible to continue
screening at least until age 60 years and not beyond age
69 years in women with adequate negative screening, but
that given increasing life expectancy, screening in older
women might be justified in the future.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001585.
N This study is further discussed in a PLOS Medicine
Perspective by Anne Rositch and colleagues
N The US National Cancer Institute provides information
about cervical cancer for patients and for health profes-
sionals, including information on cervical screening (in
English and Spanish)
N The US Centers for Disease Control and Prevention also has
information about cervical cancer and about cervical
screening
N The UK National Health Service Cervical Screening
Programme website has detailed information and statistics
on cervical screening in England
N The UK National Health Service Choices website has pages
on cervical cancer (including a personal story about
cervical cancer) and on cervical screening (including
personal comments about screening)
N Cancer Research UK provides detailed information about
all aspects of cervical cancer
N More information about cervical cancer and screening is
available from the Macmillan cancer charity
N MedlinePlus provides links to additional resources about
cervical cancer and screening (in English and Spanish)
N Personal stories about cervical cancer and about cervical
screening are available through the charity Healthtalkon-
line
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